Clinical Trials
4 trialsNCT01364415 2020-12-21
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Novartis
Phase 1 Completed
NCT01590199 2019-04-16
MACS2002
Novartis
Phase 1 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed